CN105748937A - 一种用于分化型甲状腺癌术后康复的中药组合物 - Google Patents
一种用于分化型甲状腺癌术后康复的中药组合物 Download PDFInfo
- Publication number
- CN105748937A CN105748937A CN201610323152.4A CN201610323152A CN105748937A CN 105748937 A CN105748937 A CN 105748937A CN 201610323152 A CN201610323152 A CN 201610323152A CN 105748937 A CN105748937 A CN 105748937A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- radix
- medicine composition
- thyroid carcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 88
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 230000002980 postoperative effect Effects 0.000 title claims abstract description 41
- 208000015799 differentiated thyroid carcinoma Diseases 0.000 title claims abstract description 33
- 229940079593 drug Drugs 0.000 claims abstract description 24
- 238000002360 preparation method Methods 0.000 claims abstract description 19
- 239000002775 capsule Substances 0.000 claims description 32
- 241000219099 Parthenocissus quinquefolia Species 0.000 claims description 26
- 235000009388 Parthenocissus quinquefolia Nutrition 0.000 claims description 26
- 235000005956 Cosmos caudatus Nutrition 0.000 claims description 22
- 244000293323 Cosmos caudatus Species 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 239000000284 extract Substances 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000002552 dosage form Substances 0.000 claims description 8
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 8
- 238000002137 ultrasound extraction Methods 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 5
- 238000009835 boiling Methods 0.000 claims description 4
- -1 electuary Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000004321 preservation Methods 0.000 claims description 4
- 238000004064 recycling Methods 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- 230000001954 sterilising effect Effects 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 3
- 239000008298 dragée Substances 0.000 claims description 2
- 239000002662 enteric coated tablet Substances 0.000 claims description 2
- 239000007941 film coated tablet Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000007940 sugar coated tablet Substances 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 43
- 208000024891 symptom Diseases 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 10
- 238000002474 experimental method Methods 0.000 abstract description 9
- 241001465754 Metazoa Species 0.000 abstract description 8
- 206010039491 Sarcoma Diseases 0.000 abstract description 8
- 208000011580 syndromic disease Diseases 0.000 abstract description 7
- 238000012360 testing method Methods 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 238000002560 therapeutic procedure Methods 0.000 abstract description 5
- 230000028327 secretion Effects 0.000 abstract description 4
- 231100000419 toxicity Toxicity 0.000 abstract description 4
- 230000001988 toxicity Effects 0.000 abstract description 4
- 102000011923 Thyrotropin Human genes 0.000 abstract description 3
- 108010061174 Thyrotropin Proteins 0.000 abstract description 3
- 239000002671 adjuvant Substances 0.000 abstract description 3
- 229960000874 thyrotropin Drugs 0.000 abstract description 3
- 230000001748 thyrotropin Effects 0.000 abstract description 3
- 230000005764 inhibitory process Effects 0.000 abstract description 2
- 230000014759 maintenance of location Effects 0.000 abstract description 2
- 241001290610 Abildgaardia Species 0.000 abstract 1
- 244000175448 Citrus madurensis Species 0.000 abstract 1
- 241000371967 Dysosma difformis Species 0.000 abstract 1
- 235000017317 Fortunella Nutrition 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 241000608174 Gymnadenia Species 0.000 abstract 1
- 241000830535 Ligustrum lucidum Species 0.000 abstract 1
- 241001529936 Murinae Species 0.000 abstract 1
- 241000758344 Myrsinaceae Species 0.000 abstract 1
- 241000270295 Serpentes Species 0.000 abstract 1
- 235000009754 Vitis X bourquina Nutrition 0.000 abstract 1
- 235000012333 Vitis X labruscana Nutrition 0.000 abstract 1
- 240000006365 Vitis vinifera Species 0.000 abstract 1
- 235000014787 Vitis vinifera Nutrition 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract 1
- 230000002440 hepatic effect Effects 0.000 abstract 1
- 235000011477 liquorice Nutrition 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 24
- 208000026435 phlegm Diseases 0.000 description 24
- 206010028980 Neoplasm Diseases 0.000 description 22
- 230000006870 function Effects 0.000 description 20
- 210000004072 lung Anatomy 0.000 description 16
- 210000000952 spleen Anatomy 0.000 description 16
- 210000004369 blood Anatomy 0.000 description 15
- 239000008280 blood Substances 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 14
- 208000024770 Thyroid neoplasm Diseases 0.000 description 14
- 201000002510 thyroid cancer Diseases 0.000 description 14
- 208000033781 Thyroid carcinoma Diseases 0.000 description 13
- 239000000796 flavoring agent Substances 0.000 description 13
- 235000019634 flavors Nutrition 0.000 description 13
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 13
- 231100000614 poison Toxicity 0.000 description 11
- 206010011224 Cough Diseases 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 210000001685 thyroid gland Anatomy 0.000 description 9
- 239000003440 toxic substance Substances 0.000 description 9
- 230000010354 integration Effects 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000002784 stomach Anatomy 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 230000001976 improved effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 206010025482 malaise Diseases 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 206010003549 asthenia Diseases 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 201000007227 lymph node tuberculosis Diseases 0.000 description 3
- 201000010198 papillary carcinoma Diseases 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000008736 traumatic injury Effects 0.000 description 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000002607 hemopoietic effect Effects 0.000 description 2
- 208000006454 hepatitis Diseases 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003119 painkilling effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000133570 Berberidaceae Species 0.000 description 1
- 206010006272 Breast mass Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010018498 Goitre Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 206010041497 Spermatorrhoea Diseases 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 201000000170 Thyroid lymphoma Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 210000003194 forelimb Anatomy 0.000 description 1
- 239000009860 fuzheng jiedu Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002333 glycines Chemical class 0.000 description 1
- 201000003872 goiter Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- XMBWDFGMSWQBCA-RNFDNDRNSA-M iodine-131(1-) Chemical compound [131I-] XMBWDFGMSWQBCA-RNFDNDRNSA-M 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960003918 levothyroxine sodium Drugs 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 235000015961 tonic Nutrition 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229960000716 tonics Drugs 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000005760 tumorsuppression Effects 0.000 description 1
- 208000010576 undifferentiated carcinoma Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000009530 yishen Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明属于中医药领域,公开了一种用于分化型甲状腺癌术后康复的中药组合物及其制备方法。该中药组合物由以下药用原料药制成:金橘叶、水茴香、陈皮、法半夏、包袱七、紫金牛、女贞子、麦冬、手掌参、崖棕根、蛇葡萄根、甘草。动物试验表明本发明中药组合物对小鼠肉瘤S180实体瘤具有较好的抑制作用,且药性平和,毒性低。临床试验结果表明:本发明药物可显著改善患者的中医临床症状,降低患者中医症候评分,对抑制垂体促甲状腺激素的分泌有一定的趋势;辩证治疗分化型甲状腺癌术后肝郁痰阻证患者,可减轻西医治疗的不良反应,改善患者不适症状,提高生活质量,是一种安全有效的辅助治疗方法。
Description
技术领域
本发明属于中医药领域,具体涉及一种用于分化型甲状腺癌术后康复的中药组合物及其制备方法。
背景技术
甲状腺癌是目前内分泌系统疾病中发病率最高的的恶性肿瘤,占全身恶性肿瘤的1%。一般分为乳头状癌(PTC)、滤泡细胞癌(FTC)、未分化癌,甲状腺滤泡旁细胞癌和甲状腺淋巴瘤。PTC和FTC同属分化型甲状腺癌(DTC),在甲状腺癌中其发病比例最高达90%。在患病人群中女性人数是男性的2~3倍。近期的流行病学调查提示,在世界多个国家该病的发病率表现出了较快的上升态势。
现阶段,西医治疗分化型甲状腺癌的综合方案:手术+放射性碘消融术+激素抑制治疗。西医在实施甲状腺癌根治术的同时,也带来了一定的副反应,例如131I治疗该病后,骨髓造血功能被抑制,引起白血球、血红蛋白、血小板减少,难以在短时间内恢复正常;术后疲劳乏力,颈肩部肿胀麻木、刺痛;甲状腺激素抑制疗法后情绪变化,心慌胸闷等诸多情况,严重影响了患者的生活质量。
中医学将甲状腺癌归属于“瘿瘤”范畴。甲状腺癌的病机可概括为“气”、“痰”、“瘀”、“毒”。目前越来越多的证据表明,术后中医药治疗可以改善手术本身带来的不良反应;提高免疫力,加速患者术后康复;减轻口服甲状腺素片的不良反应;软化甲状腺癌术后颈部凸起性瘢痕;减轻化疗副反应;抑制甲状腺球蛋白,降低血清甲状腺球蛋白水平,防止和延缓甲状腺癌的复发和转移等。
发明内容
发明人根据自己多年的中医临床经验,秉承中医“整体观”和“辨证论治”,并将辨证与辨病有机结合,总结传统验方和医案的治疗经验,潜心研究提供了一种用于分化型甲状腺癌术后康复的中药组合物,可有效改善分化型甲状腺癌术后多种临床症状,加速术后康复,提高患者生活质量,防止和延缓分化型甲状腺癌的复发和转移,尤其适用于术后肝郁痰阻证患者。
为实现上述所述的目的,本发明采用如下的技术方案:
一种用于分化型甲状腺癌术后康复的中药组合物,其特征在于是由以下药用原料药制成:金橘叶、水茴香、陈皮、法半夏、包袱七、紫金牛、女贞子、麦冬、手掌参、崖棕根、蛇葡萄根、甘草。
进一步优选地,一种用于分化型甲状腺癌术后康复的中药组合物,其特征在于由以下重量份配比的药用原料药制成:金橘叶8-13份、水茴香10-15份、陈皮5-8份、法半夏8-13份、包袱七10-15份、紫金牛13-18份、女贞子15-20份、麦冬10-15份、手掌参20-25份、崖棕根10-15份、蛇葡萄根6-9份、甘草3-7份。
进一步优选地,一种用于分化型甲状腺癌术后康复的中药组合物,其特征在于由以下重量份配比的药用原料药制成:金橘叶10份、水茴香12份、陈皮5份、法半夏10份、包袱七10份、紫金牛15份、女贞子16份、麦冬12份、手掌参20份、崖棕根15份、蛇葡萄根8份、甘草5份。
进一步优选地,一种用于分化型甲状腺癌术后康复的中药组合物,其特征在于由以下重量份配比的药用原料药制成:金橘叶12份、水茴香15份、陈皮6份、法半夏8份、包袱七12份、紫金牛15份、女贞子20份、麦冬15份、手掌参25份、崖棕根12份、蛇葡萄根7份、甘草4份。
本发明配伍关系解析如下:
方中:金橘叶辛苦微寒,舒肝解郁,理气散结;水茴香辛甘温,健脾利湿,理气化痰;二药伍用疏肝解郁,理气散结,健脾利湿为君药。
陈皮理气健脾,燥湿化痰;法半夏燥湿化痰;包袱七清热解毒,化痰散结,祛瘀止痛;紫金牛祛痰,活血,利尿,解毒;四药伍用化痰散结,祛瘀解毒为臣药。
崖棕根甘辛温,益气健脾,养血活血;手掌参滋补强壮,补脾润肺,安神镇惊,益气止痛,理气和血;女贞子养阴益肾,补气舒肝,滋补肝肾;麦冬养阴生津,润肺清心;蛇葡萄根清热解毒,祛风除湿,活血散结;甘草补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药,具为佐使药。
方中诸药合伍,相互作用,互为佐使,缺一不可,有疏肝行气解郁,理气化痰散结,益气养血,扶正解毒之效,能够有效改善分化型甲状腺癌术后(肝郁痰阻证)的诸多临床症状,用药安全,加速患者术后康复,提高患者生活质量,防止和延缓甲状腺癌的复发和转移。
本发明所用诸药材的性味归经及功效如下。
金橘叶:【性味】味辛;苦;性微寒。【归经】肝;脾;肺经。【功能主治】舒肝解郁;理气散结。主噎膈;瘰疬;乳房结块;乳腺炎。【用法用量】内服:煎汤,3-9g。
水茴香:【性味】味辛;甘;性温。【归经】归肺;脾;胃经。【功能主治】健脾利湿;理气化痰。主水肿;胃痛;胸腹胀满;咳嗽;小儿乳积;疮疖【用法用量】内服:煎汤,10-15g。外用:适量,捣敷;或煎水洗。
陈皮:【性味】苦、辛,温。【归经】归肺、脾经。【功能主治】理气健脾,燥湿化痰。用于胸脘胀满,食少吐泻,咳嗽痰多。
女贞子:【性味】甘、苦,凉。【归经】归肝、肾经。【功能主治】滋补肝肾,明目乌发。用于眩晕耳鸣,腰膝酸软,须发早白,目暗不明。
麦冬:【性味】甘,微苦,微寒。【归经】归心、肺、胃经。【功能主治】养阴生津,润肺清心。用于肺燥干咳。虚痨咳嗽,津伤口渴,心烦失眠,内热消渴,肠燥便秘;咽白喉。【用法用量】6~12g。
手掌参:【性味】甘;平。【归经】肺;脾;胃经。【功能主治】止咳平喘;益肾健脾;理气和血;止痛。主肺虚咳喘;虚劳消瘦;神经衰弱;肾虚腰腿酸软;阳痿;滑精;尿频;慢性肝炎;久泻;失血;带下;乳少;跌打损伤。
崖棕根:【性味】味甘;辛;性温。【归经】肺;肝;肾经。【功能主治】益气养血;活血调经。主气血虚弱;倦怠无力;心悸失眠;月经不调;经闭【用法用量】内服:煎汤,9-12g。
蛇葡萄根:【性味】辛;苦;凉。【归经】肺;肝;大肠经。【功能主治】清热解毒;祛风除湿;活血散结。主肺痛吐脓;肺痨咯血;风湿痹痛;跌打损伤;痈肿疮毒;瘰疬;癌肿。【用法用量】内服:煎汤,15-30g,鲜品倍量。
法半夏:【性味】辛、温。【归经】归脾、胃、肺经。【功能主治】燥湿化痰。用于痰多咳喘,痰饮眩悸,风痰眩晕,痰厥头痛。
包袱七:【来源】药材基源:为小檗科植物水八角莲的根和根茎。【性味】味苦;辛;性凉;有毒。【归经】肺;肝经。【功能主治】清热解毒;化痰散结;祛瘀止痛。主咽喉肿痛;痈肿;疔疮;肺炎;腮腺炎;毒蛇咬伤;瘰疬;跌打损伤。
紫金牛:【来源】为紫金牛科植物紫金牛的茎叶。全年可采,洗净,晒干。【性味】苦,平。【功能主治】镇咳,祛痰,活血,利尿,解毒。治慢性气管炎,肺结核咳嗽咯血,吐血,脱力劳伤,筋骨酸痛,肝炎,立即,急慢性肾炎,高血压,疝气,肿毒。
甘草:【性味】甘,平。【归经】归心、肺、脾、胃经。【功能主治】补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药。用于脾胃虚弱,倦怠乏力,心悸气短,咳嗽痰多,脘腹、四肢挛急疼痛,痈肿疮毒,缓解药物毒性、烈性。【用法用量】1.5~9g。
本发明的另一个目的是提供一种制备用于分化型甲状腺癌术后康复的中药组合物的方法。
为了更好的表达本发明的中药组合物,本发明的中药组合物可由金橘叶、水茴香、陈皮、法半夏、包袱七、紫金牛、女贞子、麦冬、手掌参、崖棕根、蛇葡萄根、甘草的水或/和有机溶剂提取物为活性成分,依照制剂学常规技术制成各种剂型。
本发明的上述所述中药组合物可以加入制备不同剂型时所需的各种常规辅料或辅助性成分,以常规的中药制剂制备方法制备成任何一种常用的口服制剂,例如可以是片剂、糖衣片剂、薄膜衣片剂、肠溶衣片剂、胶囊剂、硬胶囊剂、软胶囊剂、口服液、颗粒剂、冲剂、丸剂、散剂、混悬剂、粉剂。
优选地,上述所述的口服剂型为胶囊剂、片剂或颗粒剂。
最优选地,上述所述的口服剂型是胶囊剂。
一种用于分化型甲状腺癌术后康复的中药组合物胶囊剂的制备方法,其特征在于包括以下步骤:
(1)按处方取金橘叶、水茴香、紫金牛、蛇葡萄根,粉碎成平均粒径为40-60μm的颗粒后加入3-10倍量的60%的乙醇水溶液,采用超声波提取,超声波提取完毕,取滤液,减压浓缩成稠膏,得提取物A,备用,其中,提取条件包括:超声功率为150-160W,提取温度为40-50℃,提取时间为30-50min;
(2)按处方取陈皮、法半夏、包袱七、女贞子、麦冬、手掌参、崖棕根、甘草与金橘叶、水茴香、紫金牛、蛇葡萄根乙醇水提后滤渣加水煎煮两次,第一次加4-10倍重量份的水,煎煮1.0-2.0小时,第二次加3-6重量份的水煎煮1.0-1.5小时,合并煎液,滤过,滤液减压浓缩至相对密度为1.05-1.10(60℃测得)后,加入乙醇至浓度为30%,于-5~5℃冷藏12小时,滤过,滤液回收乙醇,浓缩得稠膏,得提取物B,与提取物A混合均匀,在进风温度140~150℃,出风温度75~80℃条件下进行喷雾干燥,得颗粒,过筛、灭菌、装入胶囊壳即得本发明胶囊剂。
本发明的制剂在使用时根据病人的情况确定用法用量。本发明的胶囊剂在使用时根据病人的情况确定用法用量,可每日服1-3次,每次1-20粒。
本发明还请求保护上述所述中药组合物在制备用于甲状腺癌术后康复药物中的用途,尤其适用于辩证用于甲状腺癌术后肝郁痰阻患者。本发明实施例8-9的动物试验表明:本发明中药组合物对小鼠肉瘤S180实体瘤具有较好的抑制作用,且药性平和,毒性低;实施例10的本发明临床试验结果表明:本发明药物可显著改善患者的中医临床症状,降低患者中医症候评分,与西药治疗组比较差异有统计学意义,本发明药物治疗组的临床总有效率为94.9%,而对照组仅为76.3%;本发明药物对抑制垂体促甲状腺激素的分泌有一定的趋势;治疗分化型甲状腺癌术后患者,可减轻西医治疗的不良反应,改善患者不适症状,提高生活质量,是一种安全有效的辅助治疗方法。
总之与现有技术相比,本发明具有以下有益效果:
(1)本发明药性平和,动物试验和临床试验均表明本发明药物安全系数高,不良反应少。
(2)本发明以中医理论为基础,组方严谨,君臣佐使配伍关系明确,选药精当,具有多靶点、多环节、多层次的综合调控作用,辩证用于甲状腺癌术后肝郁痰阻证患者,可显著改善甲状腺癌术后患者的多种症状,加速术后康复,提高患者生活质量。
(3)本发明药物可防止和延缓甲状腺癌的复发和转移,临床总有效率高。
(4)本发明可以制备成多种口服制剂,避免了服用不便,患者依从性差的缺点。
具体实施方式
以下通过具体实施例进一步描述本发明,本发明不仅仅限于以下实施例。在本发明的范围内或者在不脱离本发明的内容、精神和范围内,对本发明进行的变更、组合或替换,对于本领域的技术人员来说是显而易见的,且包含在本发明的范围之内。
实施例1胶囊剂
处方:金橘叶10份、水茴香12份、陈皮5份、法半夏10份、包袱七10份、紫金牛15份、女贞子16份、麦冬12份、手掌参20份、崖棕根15份、蛇葡萄根8份、甘草5份。
制备方法:(1)按处方取金橘叶、水茴香、紫金牛、蛇葡萄根,粉碎成平均粒径为45-50μm的颗粒后加入7倍量的60%的乙醇水溶液,采用超声波提取,超声波提取完毕,取滤液,减压浓缩成稠膏,得提取物A,备用,其中,提取条件包括:超声功率为150-160W,提取温度为40-50℃,提取时间为40-50min;
(2)按处方取陈皮、法半夏、包袱七、女贞子、麦冬、手掌参、崖棕根、甘草与金橘叶、水茴香、紫金牛、蛇葡萄根乙醇水提后滤渣加水煎煮两次,第一次加7倍重量份的水,煎煮1.0-2.0小时,第二次加4重量份的水煎煮1.0-1.5小时,合并煎液,滤过,滤液减压浓缩至相对密度为1.07(60℃测得)后,加入乙醇至浓度为30%,于-5~5℃冷藏12小时,滤过,滤液回收乙醇,浓缩得稠膏,得提取物B,与提取物A混合均匀,在进风温度140~150℃,出风温度75~80℃条件下进行喷雾干燥,得颗粒,过筛、灭菌、装入胶囊壳即得。本实施例胶囊剂每粒装量0.35g,相当于生药1.04g。
实施例2胶囊剂
处方:金橘叶12份、水茴香15份、陈皮6份、法半夏8份、包袱七12份、紫金牛15份、女贞子20份、麦冬15份、手掌参25份、崖棕根12份、蛇葡萄根7份、甘草4份。
制备方法:(1)按处方取金橘叶、水茴香、紫金牛、蛇葡萄根,粉碎成平均粒径为50-60μm的颗粒后加入8倍量的60%的乙醇水溶液,采用超声波提取,超声波提取完毕,取滤液,减压浓缩成稠膏,得提取物A,备用,其中,提取条件包括:超声功率为150-160W,提取温度为40-50℃,提取时间为35-45min;
(2)按处方取陈皮、法半夏、包袱七、女贞子、麦冬、手掌参、崖棕根、甘草与金橘叶、水茴香、紫金牛、蛇葡萄根乙醇水提后滤渣加水煎煮两次,第一次加7倍重量份的水,煎煮1.0-2.0小时,第二次加5重量份的水煎煮1.0-1.5小时,合并煎液,滤过,滤液减压浓缩至相对密度为1.08(60℃测得)后,加入乙醇至浓度为30%,于-5~5℃冷藏12小时,滤过,滤液回收乙醇,浓缩得稠膏,得提取物B,与提取物A混合均匀,在进风温度140~150℃,出风温度75~80℃条件下进行喷雾干燥,得颗粒,过筛、灭菌、装入胶囊壳即得。本实施例胶囊剂每粒装量0.35g,相当于生药1.06g。
实施例3胶囊剂
处方:金橘叶8份、水茴香12份、陈皮8份、法半夏12份、包袱七12份、紫金牛13份、女贞子16份、麦冬15份、手掌参20份、崖棕根12份、蛇葡萄根9份、甘草5份。
制备方法:参照实施例1-2的操作进行。
实施例4胶囊剂
处方:金橘叶10份、水茴香10份、陈皮6份、法半夏8份、包袱七12份、紫金牛15份、女贞子15份、麦冬15份、手掌参20份、崖棕根12份、蛇葡萄根8份、甘草6份。
制备方法:参照实施例1-2的操作进行。
实施例5胶囊剂
处方:金橘叶12份、水茴香10份、陈皮8份、法半夏12份、包袱七10份、紫金牛18份、女贞子17份、麦冬12份、手掌参22份、崖棕根12份、蛇葡萄根8份、甘草5份。
制备方法:参照实施例1-2的操作进行。
实施例6胶囊剂
处方:金橘叶10份、水茴香12份、陈皮8份、法半夏12份、包袱七15份、紫金牛13份、女贞子15份、麦冬12份、手掌参20份、崖棕根15份、蛇葡萄根7份、甘草4份。
制备方法:参照实施例1-2的操作进行。
实施例7胶囊剂
处方:金橘叶8份、水茴香15份、陈皮8份、法半夏12份、包袱七12份、紫金牛18份、女贞子18份、麦冬12份、手掌参22份、崖棕根12份、蛇葡萄根8份、甘草5份。
制备方法:参照实施例1-2的操作进行。
实施例8毒理学实验
(一)急性毒性实验:选取昆明小鼠60只,雌雄各半,体重22~32g,随机分为四组,即对照组和给药组,实验前禁食12小时,将本发明的实施例1-2制备的中药胶囊剂溶解在水中制成混悬液(浓度为5.2g-5.3g生药/ml,最高浓度)灌胃,灌胃容积为5ml/kg,对照组给予等量生理盐水,一天给药2次,给药间隔时间6小时,给药后连续观察14天,并记录小鼠的的毒性反应及死亡数。
实验结果表明:与对照组比较,给药后各组小鼠未见明显差异,实验连续观察14天,小鼠全身状况、饮食、饮水、体重增长均正常。小鼠口服灌胃本发明的胶囊即LD50>26-26.5g生药/kg,每日最大给药量为53.0g生药/kg/日。因此本发明的中药急性毒性极低,临床用药安全。
(二)长期毒性实验:本发明中药实施例1胶囊剂对小鼠按1.04、2.1和4.2g生药/kg连续用药15周(1.0ml/100g体重,每天2次)及停药3周后,结果表明:本发明中药对小鼠的毛发、行为、大小便、体重、脏器重量、血象、肝肾功能、血糖、血脂等指标均无明显影响,脏器肉眼没有发现异样变化和组织学检查结果表明,用药15周及停药3周后,小鼠各脏器均无明显改变。说明本发明中药对小鼠长期用药后毒性小,停药后也没有异样反应,应用安全。
实施例9本发明中药组合物对小鼠肉瘤S180实体瘤的影响
1.1实验材料
1.1.1受试动物:ICR小鼠60只,雌性,体重18~22g,由山东医学科学院动物实验中心提供。
1.1.2受试药物:实施例1制备的胶囊剂内容物。
1.1.3对照药物注射用环磷酰胺(CTX):200mg/瓶,德国BaxterOncologyGmbh公司。
1.1.4细胞株S180肉瘤,浙江中医药大学实验动物中心。
1.2实验方法:
1.2.1S180肉瘤小鼠模型制备与分组:无菌条件下取接种S180瘤株6-7天的小鼠的腹水(为乳白色浓稠腹水瘤液,若为黄色或红色则应弃去不用),以生理盐水稀释,调细胞浓度至1x107个/mL。按0.2mL每只接种于小鼠前肢右腋皮下。接种后随机分为阳性对照组、阴性对照组、本发明胶囊剂低剂量组、中剂量组、高剂量组,每组12只。
1.2.2给药:接种24h后阴性对照组采用0.2mL/10g生理盐水灌胃,每天一次。阳性对照组采用环磷酰胺腹腔注射,20mg/kg,每天1次。本发明胶囊剂低、中、高剂量组分别给予本发明中药胶囊剂0.13g/kg、0.26g/kg、1.04g/kg灌胃给药,0.2mL/10g,每天1次。观察10天停药。停药次日处死动物,称体质量,剥离皮下瘤体并称重。
1.2.3数据收集与检测:在观察期间记录小鼠的一般情况(饮食、外观、行为、分泌物、排泄物、中毒表现和死亡情况等),定期称重,停药次日处死动物,称体质量,剥离皮下瘤体称重。计算肿瘤生长抑制率,计算公式如下:抑瘤率(IR)=(阴性对照组-实验组平均瘤重÷阴性对照组平均瘤重)×100%。以瘤重有显著性差异,且肿瘤抑制率>30%为药物具有抗肿瘤活性的标准。
1.3实验结果:
在观察期间小鼠的一般状态良好,接种约5天后可观察到小鼠腋下有黄豆大小的瘤体长出,随着瘤体的增大,部分小鼠进食进水减少、活动减少、毛发凌乱。实验期间,无小鼠死亡。
本发明的中药组合物中、高剂量组和阳性对照组对S180肉瘤实体瘤小鼠的肿瘤生长都有明显的抑制作用,抑制率分别为35.9%、39.5%、54.3%。本发明中药胶囊中、高剂量组瘤重与生理盐水组相比,都有显著差异(P<0.05),CTX组与生理盐水组相比,瘤重有非常显著差异(P<0.01)。见表1。
表1本发明中药组合物对小鼠肉瘤S180实体瘤的影响(n=10)
注:与对照组比较,*P<0.05,**P<0.01。
实验结果表明,本发明药物对S180肉瘤实体瘤小鼠肿瘤生长具有明显的抑制作用,能较平稳地抑瘤,与生理盐水组相比有显著性差异,可为临床应用提供理论依据。
实施例10本发明中药组合物对分化型甲状腺癌术后患者的临床观察试验
1资料与方法
1.1一般资料:77例甲状腺癌术后病理均确诊为分化型甲状腺癌患者,来自2013年5月-2014年7月我院内分泌科,其中乳头状癌65例,伴颈淋巴结转移48例,滤泡亚型乳头状癌12例,伴颈淋巴结转移6例;采用随机数字表法随机分为治疗组和对照组,治疗组39例,对照组38例。治疗组,男5例,女34例;平均年龄33.6±8.4岁;对照组男4例,女34例;平均年龄32.8±8.1岁;两组预计生存期>6个月,两组在性别、年龄、癌症类别等一般资料的差异无统计学意义(P>0.05),具有可比性。
1.2诊断标准:
1.2.1甲状腺癌诊断标准:经术前B超、甲状腺核素扫描或针吸活组织检查确诊,并经术后病理证实诊断为分化型甲状腺癌;伴或不伴有甲状腺功能异常;
1.2.2中医辨证:参照《中药新药临床研究指导原则》及《中医临床诊疗术语国家标准(证候部分)》定制为肝郁痰阻证,临床表现为目眩头晕、口干、乏力、多梦、情志抑郁、肢体倦怠、心烦易怒、胸胁不舒、舌红、苔白、脉细、薄苔、脉沉等。中医症状评分:1分:症状无或消失;2分:症状轻微,偶有;3分:症状明显影响生活;4分:症状严重影响生活。分别在治疗前及治疗后记录。
1.3病例排除标准:妊娠、哺乳期妇女、肝功能异常者;合并有心血管、肝、肾和造血系统等严重原发性疾病,精神病患者;接受其他中药、糖皮质激素及其它免疫抑制剂治疗者;近三月内参加其他药物临床试验者。
1.4治疗方法:
对照组:给予左甲状腺素钠片治疗,根据甲状腺功能调整剂量。治疗组:在对照组治疗的基础上加用本发明实施例1制备的胶囊治疗,一日两次,每次4-6粒。两组均以1月为1疗程,3个疗程结束后进行疗效观察。
1.5疗效评定标准:综合疗效判定标准:计算公式:(治疗前积分-治疗后积分)/治疗前积分,以百分数表示。痊愈:症状体征基本消失,积分大于或等于90%;显效:症状体征明显改善,积分大于或等于75%;有效:症状体征有好转,积分大于或等于35%;无效:症状体征无明显改善,甚或加重,积分不足35%。
1.6统计学分析采用spss16.0统计软件进行分析,计数资料两样本率的比较采用X2检验,计量资料以表示,治疗前后比较用配对t检验,组间比较采用t检验,P<0.05表示差异有统计学意义。
2结果
2.1治疗后两组患者临床疗效比较:3个疗程后,治疗组治愈13例,显效18例,有效6例,总有效率94.9%;而对照组治愈5例,显效8例,有效16例,总有效率76.3%,治疗组的治疗效果明显优于对照组。见表2。
表2治疗后两组患者临床疗效比较,例(%)
注:与对照组比较,*P<0.01。
2.2两组治疗前后证候总积分比较,见表3。两组治疗后证候积分均显著改善,与治疗前比较,差异均有显著性意义(P<0.05,P<0.01);治疗后两组间比较,差异也有显著性意义(P<0.05),治疗组中医症候总积分减少的更加明显。见表3。
表3两组治疗前后症候总积分比较
注:与治疗前比较,*P<0.05,**P<0.01;两组间比较,#P<0.05。
2.3两组甲状腺功能治疗前后的变化:治疗后两组FT3、FT4均明显升高、TSH明显下降,与治疗前比较差异有统计学意义(P<0.05);治疗后比较两组组间甲状腺功能变化,FT3、FT4均上升,TSH均下降,治疗组甲状腺功能变化幅度较对照组略大,但组间比较差异无统计学意义(P>0.05),见表4。
表4两组甲状腺功能治疗前后的变化
注:同组治疗前比较,*P<0.05,**P<0.01。
2.4不良反应及安全性检测:治疗组在观察期间,FT3、FT4及TSH并无明显变化,说明中药组合物对于甲状腺分泌激素的功能影响很小,治疗组病人无任何主观不适,血、尿、大便常规及心、肝、肾功能等检查均未出现异常。
本研究显示,本发明药物可显著改善患者的中医临床症状,降低患者中医症候评分;对抑制垂体促甲状腺激素的分泌有一定的趋势;治疗分化型甲状腺癌术后患者,可减轻西医治疗的不良反应,改善患者不适症状,提高生活质量,是一种安全有效的辅助治疗方法。
Claims (10)
1.一种用于分化型甲状腺癌术后康复的中药组合物,其特征在于由以下药用原料药制成:金橘叶、水茴香、陈皮、法半夏、包袱七、紫金牛、女贞子、麦冬、手掌参、崖棕根、蛇葡萄根、甘草。
2.如权利要求1所述的用于分化型甲状腺癌术后康复的中药组合物,其特征在于由以下重量份配比的药用原料药制成:金橘叶8-13份、水茴香10-15份、陈皮5-8份、法半夏8-13份、包袱七10-15份、紫金牛13-18份、女贞子15-20份、麦冬10-15份、手掌参20-25份、崖棕根10-15份、蛇葡萄根6-9份、甘草3-7份。
3.如权利要求2所述的用于分化型甲状腺癌术后康复的中药组合物,其特征在于由以下重量份配比的药用原料药制成:金橘叶10份、水茴香12份、陈皮5份、法半夏10份、包袱七10份、紫金牛15份、女贞子16份、麦冬12份、手掌参20份、崖棕根15份、蛇葡萄根8份、甘草5份。
4.如权利要求2所述的用于分化型甲状腺癌术后康复的中药组合物,其特征在于由以下重量份配比的药用原料药制成:金橘叶12份、水茴香15份、陈皮6份、法半夏8份、包袱七12份、紫金牛15份、女贞子20份、麦冬15份、手掌参25份、崖棕根12份、蛇葡萄根7份、甘草4份。
5.如权利要求1-4任一所述的用于分化型甲状腺癌术后康复的中药组合物,其特征在于所述中药组合物优选制成为口服剂型。
6.如权利要求5所述的用于分化型甲状腺癌术后康复的中药组合物,其特征在于所述口服剂型为片剂、糖衣片剂、薄膜衣片剂、肠溶衣片剂、胶囊剂、硬胶囊剂、软胶囊剂、口服液、颗粒剂、冲剂、丸剂、散剂、混悬剂、粉剂。
7.如权利要求5所述的用于分化型甲状腺癌术后康复的中药组合物,其特征在于所述口服剂型进一步优选为胶囊剂、片剂或颗粒剂。
8.如权利要求7所述的用于分化型甲状腺癌术后康复的中药组合物,其特征在于所述口服剂型进一步优选为胶囊剂。
9.如权利要求1-8所述的用于分化型甲状腺癌术后康复的中药组合物,其特征在于所述胶囊剂的制备方法,包括以下步骤:
(1)按处方取金橘叶、水茴香、紫金牛、蛇葡萄根,粉碎成平均粒径为40-60μm的颗粒后加入3-10倍量的60%的乙醇水溶液,采用超声波提取,超声波提取完毕,取滤液,减压浓缩成稠膏,得提取物A,备用,其中,提取条件包括:超声功率为150-160W,提取温度为40-50℃,提取时间为30-50min;
(2)按处方取陈皮、法半夏、包袱七、女贞子、麦冬、手掌参、崖棕根、甘草与金橘叶、水茴香、紫金牛、蛇葡萄根乙醇水提后滤渣加水煎煮两次,第一次加4-10倍重量份的水,煎煮1.0-2.0小时,第二次加3-6重量份的水煎煮1.0-1.5小时,合并煎液,滤过,滤液减压浓缩至相对密度为1.05-1.10(60℃测得)后,加入乙醇至浓度为30%,于-5~5℃冷藏12小时,滤过,滤液回收乙醇,浓缩得稠膏,得提取物B,与提取物A混合均匀,在进风温度140~150℃,出风温度75~80℃条件下进行喷雾干燥,得颗粒,过筛、灭菌、装入胶囊壳即得。
10.权利要求1-4任一所述的中药组合物在制备用于分化型甲状腺癌术后康复药物中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610323152.4A CN105748937A (zh) | 2016-05-16 | 2016-05-16 | 一种用于分化型甲状腺癌术后康复的中药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610323152.4A CN105748937A (zh) | 2016-05-16 | 2016-05-16 | 一种用于分化型甲状腺癌术后康复的中药组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105748937A true CN105748937A (zh) | 2016-07-13 |
Family
ID=56324045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610323152.4A Withdrawn CN105748937A (zh) | 2016-05-16 | 2016-05-16 | 一种用于分化型甲状腺癌术后康复的中药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105748937A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108815472A (zh) * | 2018-08-29 | 2018-11-16 | 河南中医药大学 | 一种改善甲状腺癌患者术后抑郁状态的中药 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102120007A (zh) * | 2011-02-15 | 2011-07-13 | 龙再颖 | 一种防治131i治疗分化型甲状腺癌后并发症的药物 |
-
2016
- 2016-05-16 CN CN201610323152.4A patent/CN105748937A/zh not_active Withdrawn
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102120007A (zh) * | 2011-02-15 | 2011-07-13 | 龙再颖 | 一种防治131i治疗分化型甲状腺癌后并发症的药物 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108815472A (zh) * | 2018-08-29 | 2018-11-16 | 河南中医药大学 | 一种改善甲状腺癌患者术后抑郁状态的中药 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101947284B (zh) | 一种治疗糖尿病的中药组合物及其制备方法 | |
CN104225441A (zh) | 一种治疗胃病的中药组合物及其颗粒剂和胶囊剂的制备方法 | |
CN101716318B (zh) | 一种用于辅助化疗方式治疗消化系统肿瘤的中药制剂 | |
CN103099966A (zh) | 一种健胃益脾饮剂 | |
CN104922543A (zh) | 一种治疗闭经的药物组合物及其制备方法 | |
CN105456897A (zh) | 一种含有艾叶的治疗脾虚胃弱型慢性胃炎的中药组合物 | |
CN101780136A (zh) | 一种具有抗肿瘤活性和免疫调节作用的药食两用中药组合物及应用 | |
CN101711848B (zh) | 一种辅助治疗肿瘤的中药组合物 | |
CN105748937A (zh) | 一种用于分化型甲状腺癌术后康复的中药组合物 | |
CN104257977A (zh) | 一种治疗肝胃不和型慢性浅表性胃炎的中药制剂 | |
CN114748603A (zh) | 一种防治新冠病毒肺炎变异或复阳的药食同源组合物和应用 | |
CN114947127A (zh) | 提高肿瘤患者免疫力的保健食品组合物及制备方法和应用 | |
CN104906551B (zh) | 一种抗疲劳中药组合物和制备方法 | |
CN103990009A (zh) | 一种健脾泄浊法治疗ⅱ型糖尿病中药 | |
CN106511915A (zh) | 一种复方中药组合物在抑制皮肤黑色素瘤肺转移药物中的应用 | |
CN106072556A (zh) | 用于调节血糖的保健食品及其制备方法 | |
CN105343808A (zh) | 一种具有减肥效果的中药组合物及其制备方法 | |
CN105267818A (zh) | 一种治疗胃脘痛的中药组合物及其制备方法 | |
CN104147277A (zh) | 一种治疗重症肌无力的中药制剂及制备方法 | |
CN104606538A (zh) | 一种用于预防和治疗糖尿病的中药保健品 | |
CN104623605A (zh) | 治疗乳腺癌的中药 | |
CN103705857B (zh) | 用于预防放射性口腔粘膜反应的中药组合物 | |
CN102579713B (zh) | 治疗儿童肥胖症的中药及制备方法 | |
CN105770265A (zh) | 一种用于食道癌的药物制剂及其用途 | |
CN105770520A (zh) | 一种用于治疗冠心病的药物制剂及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160713 |
|
WW01 | Invention patent application withdrawn after publication |